



Clinical Research Trials

Last Updated: 06/02/2023

Monument Health Cancer Care Institute

Brain	Trial Title	ClinicalTrials.gov Link
-------	-------------	-------------------------

Anaplastic Glioma (N0577)	Phase III Intergroup Study of Radiotherapy vs Temozolomide Alone vs Radiotherapy with Concomitant and Adjuvant Temozolomide for Patient with 1p/19q Codeleted Anaplastic Glioma	https://clinicaltrials.gov/ct2/show/NCT00887146?id=n0577&rank=1
Glioblastoma (BN011)	A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma	https://clinicaltrials.gov/ct2/show/NCT05095376?id=bn011&draw=2&rank=1

Breast	Trial Title	ClinicalTrials.gov Link
--------	-------------	-------------------------

Breast (A011801)	The COMPASSHER2 Trials (COMprehensive use of Pathologic Response ASsessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DMI and Placebo Compared with T-DMI and Tucatinib	https://clinicaltrials.gov/ct2/show/NCT04457596?id=a011801&draw=2&rank=1
GS-US-595-6184	Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05)	https://clinicaltrials.gov/ct2/show/NCT05633654?term=05633654&draw=2&rank=1
S2010	A randomized phase III trial comparing active symptom monitoring plus patient education versus patient education alone to improve persistence with endocrine therapy in young women with Stage I-III breast cancer (ASPEN)	https://clinicaltrials.gov/ct2/show/NCT05568472?id=NCT05568472&draw=2&rank=1

Gastrointestinal (GI)	Trial Title	ClinicalTrials.gov Link
-----------------------	-------------	-------------------------

Colon (NRG-GI005)	Phase II/III Study of Circulating tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with ColonStage IIA colon Cancer (COBRA)	https://clinicaltrials.gov/ct2/show/NCT04068103?lead=NRG&id=gi005&draw=2&rank=1
Colon (NRG-GI008)	Colon Adjuvant Chemotherapy Based on Evaluation of residual Disease (CIRCULATE-US)	https://clinicaltrials.gov/ct2/show/NCT05174169?id=gi008&draw=2&rank=1
Esophagus (A022102)	Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma	https://clinicaltrials.gov/ct2/show/NCT05677490?id=NCT05677490&draw=2&rank=1
Gastro-Oesophageal (AG0315OG/CTC140)	A Randomised Phase III Open Label Study of regorafenib + nivolumab vs standard chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) study	https://clinicaltrials.gov/ct2/show/NCT04879368?id=AG0315og%2Fctc0140&draw=2&rank=1
Hepatocellular (GI-2008)	A Phase II Randomized Study of Atezolizumab plus Multi-Kinase Inhibitor Versus Multi-Kinase Inhibitor Alone in Subjects with Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab and Bevacizumab	https://clinicaltrials.gov/ct2/show/NCT05168163?id=Gi-2008&draw=2&rank=1

Pancreatic (EA2186)	A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)	https://clinicaltrials.gov/ct2/show/NCT04233866?id=ea2186&draw=2&rank=1
Pancreatic (S2001)	Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations	https://clinicaltrials.gov/ct2/show/NCT04548752?id=s2001&draw=2&rank=2

Genitourinary (GU)	Trial Title	ClinicalTrials.gov Link
Urinary Tract (A032001)	MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab after First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer	https://clinicaltrials.gov/ct2/show/NCT05092958?id=a032001&draw=2&rank=1
Urinary Tract (S2011)	Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin vs NoNeoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligibile Muscle-Invasive Urothelial Carcinoma: SWOG GAP TRIAL	https://clinicaltrials.gov/ct2/show/NCT04871529?id=s2011&draw=2&rank=1
Prostate (NRG-GU009)	Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)	https://clinicaltrials.gov/ct2/show/NCT04513717?id=gu009&draw=2&rank=1
Prostate (NRG-GU010)	Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (Guidance)	https://clinicaltrials.gov/ct2/show/NCT05050084?id=nrg+gu010&draw=2&rank=1
Prostate (A031902)	A phase 2 trial of ADT interruption in patients responding exceptionally to AR pathway inhibitor in metastatic hormone-sensitive prostate cancer (MHSPC): A-DREAM	https://clinicaltrials.gov/ct2/show/NCT04455750?id=A031902&draw=2&rank=1
Prostate (A032101)	MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab after First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer	https://clinicaltrials.gov/ct2/show/NCT05241860?id=a032101&draw=2&rank=1

Gynecologic	Trial Title	ClinicalTrials.gov Link
GYN (GY026)	A Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) or pertuzumab trastuzumab and hyaluronidase-zzfx (PHESGO) in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma	https://clinicaltrials.gov/ct2/show/NCT05256225?id=GY026&draw=2&rank=1
GYN (CORT125134-556)	A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)	https://clinicaltrials.gov/ct2/show/NCT05257408?id=CORT125134-556&draw=2&rank=1
GYN (EAY191-N4)	Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial	https://clinicaltrials.gov/ct2/show/NCT05554328?term=05554328&draw=2&rank=1
GYN (GY019)	A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum	https://clinicaltrials.gov/ct2/show/NCT04095364?id=GY019&draw=2&rank=1
(Genetic Testing) ZN-c3-005	A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High_Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	https://clinicaltrials.gov/ct2/show/NCT05128825?id=zn-c3-005&draw=2&rank=1

Head and Neck	Trial Title
---------------	-------------

Head and Neck (EA3202)	A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers	https://clinicaltrials.gov/ct2/show/NCT05063552?id=ea3202&draw=2&rank=1
------------------------	--	---

Hematologic	Trial Title	ClinicalTrials.gov Link
Myelodysplastic Syndromes (NHLBI-MDS)	The National Myelodysplastic Syndromes (MDS) Study	https://clinicaltrials.gov/ct2/show/NCT02775383?id=nhlbi-mds&rank=1
Multiple Myeloma (EAA181)	Effective Quadruplet Utilization after Treatment Evaluation (EQUATE): A randomized phase III trial for newly diagnosed Multiple Myeloma not intended for early autologous transplantation	https://clinicaltrials.gov/ct2/show/NCT04566328?id=EAA181&draw=2&rank=1
Lymphoma (S1918)	A Phase II/III Randomized Study of R-miniCHOP with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIb Follicular Lymphoma, Transformed lymphoma, and High-Grade B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements	https://clinicaltrials.gov/ct2/show/NCT04799275?id=S1918&draw=2&rank=1

Lung		ClinicalTrials.gov Link
Small Cell (JZP712-402)	Phase IV Zepzelca Observational Study in Extensive Stage SCLC	https://clinicaltrials.gov/ct2/show/NCT04894591?id=jzp712-402&draw=2&rank=1
Non-Small Cell (LUNGMAP)	A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (LUNG-MAP Screening Study)	https://clinicaltrials.gov/ct2/show/NCT03851445?id=lungmap&draw=2&rank=1
Non-Small Cell (S1900E)	A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-map Sub-study)	https://clinicaltrials.gov/ct2/show/NCT04625647?id=S1900E&draw=2&rank=1
Non-Small Cell (S1900F)	A Randomized Phase II Study of Carboplatin and Pemetrexed with or without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)	https://clinicaltrials.gov/ct2/show/NCT05364645?id=s1900f&draw=2&rank=1
Non-Small Cell (S1900G)	A randomized phase II study of INC280 (capmatinib) plus Osimertinib with or without Ramucirumab in participants with EGFR-mutant, MET-amplified stage IV or recurrent NSCLC (LUNG-MAP Sub-Study)	https://clinicaltrials.gov/ct2/show/NCT05642572?cond=NCT05642572&draw=2&rank=1
Non-Small Cell (S2302)	A prospective randomized study of Ramucirumab plus Pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer	https://clinicaltrials.gov/ct2/show/NCT05633602?id=s2302&draw=2&rank=1
Non-Small Cell (EA5182)	Randomized Phase 3 Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Lung Cancer	https://clinicaltrials.gov/ct2/show/NCT04181060?id=ea5182&draw=2&rank=1
Non-Small Cell (EA5181)	Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC	https://clinicaltrials.gov/ct2/show/NCT04092283?id=ea5181&draw=2&rank=1

Melanoma		ClinicalTrials.gov Link
Melanoma (EA6141)	Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma	https://clinicaltrials.gov/ct2/show/NCT02339571?id=Ea6141&draw=2&rank=1

Symptom Management/Other	Trial Title	ClinicalTrials.gov Link
--------------------------	-------------	-------------------------

Anorexia (A222004)	A Randomized Phase III Trial of Olanzapine versus Megestrol Acetate for Cancer-Associated Anorexia	https://clinicaltrials.gov/ct2/show/NCT04939090?id=a222004&draw=2&rank=1
Neuropathy (SC-2102)	Treatment of Established Chemotherapy-Induced Neuropathy with N-Palmitoylethanolamide, a Cannabimimetic Nutraceutical: A Randomized Double-Blind Phase II Pilot Trial	https://clinicaltrials.gov/ct2/show/NCT05246670?cond=neuropathy&id=ACCRU+SC-2102&draw=2&rank=1